Helical raises $10M to bridge the gap between foundation models and drug discovery decisions
This image was generated by AI and may not depict real events.
Helical, a pharma artificial intelligence startup, has raised $10 million in funding to expand its virtual AI lab platform. The platform aims to bridge the gap between foundation models and drug discovery decisions by turning biological foundation models into reproducible in-silico drug discovery workflows.
Helical, a pharma AI startup, has raised $10 million in funding. The company's virtual AI lab platform turns biological foundation models into reproducible drug discovery workflows. Founded in 2024, Helical addresses the gap between computational outputs and biological decision-making. The platform offers two product surfaces: a Virtual Lab for biologists and The Model Factory for machine learning engineers. Helical is already in production with top global pharma companies, including Pfizer. The funding round was led by Redalpine Venture Partners AG.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.